Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 3Genitourinary 3Gynecologic 2Breast 2Sarcoma 1Other hematologic neoplasm 1

Conditions

Ovarian Neoplasms 2Lymphoma 2Breast Neoplasms 2Neoplasms 1Neoplasm Metastasis 1Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Paclitaxel 108Carboplatin 97pembrolizumab 64Cisplatin 63Cyclophosphamide 45Bevacizumab 35Taxes 31Gemcitabine 28liposomal doxorubicin 27Topotecan 26fludarabine 25olaparib 22Nivolumab 20Docetaxel 20Radiotherapy 18Brachytherapy 17veliparib 16Magnetic Resonance Spectroscopy 16Doxorubicin 16Biopsy 15Radiation 14niraparib 13aldesleukin 13Specimen Handling 13Platinum 13Oxaliplatin 13Filgrastim 13Albumin-Bound Paclitaxel 12atezolizumab 11Interleukin-2 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × valspodar × Gynecologic × Clear all
NCT00001302 2008-03-04

A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
80 enrolled
BreastGenitourinaryGynecologicLymphoid

Breast Neoplasms, Kidney Neoplasms, Lymphoma, Neoplasm Metastasis, Ovarian Neoplasms

NCT00001383 2008-03-04

A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
52 enrolled
BreastGenitourinaryGynecologicLymphoid

Breast Neoplasms, Carcinoma, Renal Cell, Lymphoma, Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡